Repligen Corporation
$ 122.31
-3.35%
05 Jun - close price
- Market Cap 6,899,231,000 USD
- Current Price $ 122.31
- High / Low $ 128.36 / 121.69
- Stock P/E 134.41
- Book Value 37.33
- EPS 0.91
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.03 %
- 52 Week High 175.77
- 52 Week Low 100.99
About
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$176.11
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-24 | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-20 | 2024-11-12 | 2024-07-30 | 2024-05-01 | 2024-02-21 | 2023-10-31 | 2023-08-02 |
| Reported EPS | 0.48 | 0.49 | 0.46 | 0.37 | 0.39 | 0.44 | -0.0117 | 0.33 | 0.28 | 0.33 | 0.23 | 0.53 |
| Estimated EPS | 0.39 | 0.4394 | 0.41 | 0.39 | 0.35 | 0.4191 | 0.33 | 0.33 | 0.3 | 0.33 | 0.16 | 0.48 |
| Surprise | 0.09 | 0.0506 | 0.05 | -0.02 | 0.04 | 0.0209 | -0.3417 | 0 | -0.02 | 0 | 0.07 | 0.05 |
| Surprise Percentage | 23.0769% | 11.5157% | 12.1951% | -5.1282% | 11.4286% | 4.9869% | -103.5455% | 0% | -6.6667% | 0% | 43.75% | 10.4167% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.45 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGEN
2026-06-05 23:10:01
Repligen Corp (RGEN) shares surged 4.0% to $126.55 on June 4, 2026. The stock is considered 27.7% undervalued according to GuruFocus' GF Value™ estimate of $174.94, despite its current P/E (TTM) of 140.6x being significantly above its 5-year median. The company holds a GF Score™ of 79/100, indicating strong growth and financial strength, though recent insider selling of $0.5 million suggests caution for investors.
2026-06-04 15:08:45
Repligen (RGEN) shares have dropped 3.2% since its last earnings report, underperforming the S&P 500. Despite this, the company's Q1 2026 adjusted earnings and revenues surpassed estimates, with strong year-over-year growth across its business franchises. While Repligen lowered its full-year 2026 revenue guidance, it raised its EPS outlook, leading to varied analyst sentiment and a Zacks Rank #3 (Hold).
2026-06-02 18:08:45
Repligen (RGEN) reported a strong Q1 2026 with 15% revenue growth, including 11% organic growth, indicating a renewed focus on margin expansion and portfolio quality after a challenging previous year. The company's robust balance sheet and cash generation offer flexibility for M&A and expansion, particularly into higher-value bioprocessing areas and global markets. This strategic pivot, including the opening of a new Training & Innovation Center, reinforces its long-term investment narrative despite ongoing risks related to customer concentration and volatile market segments.
2026-06-02 17:39:28
This article provides a financial snippet for Repligen Corporation (SWB:RGN), specifically focusing on its total current liabilities. It shows the period, value, and percentage change of these liabilities. The content appears to be a stub from a financial data platform like TradingView, lacking detailed analysis or a full report.
2026-06-02 05:40:36
Wolfe Research initiated coverage on Repligen Corp. (NASDAQ:RGEN) with an outperform rating and a price target of $145.00, representing 60 times the firm’s 2027 EPS estimate. The firm's analysis supports this valuation if Repligen achieves 15% annual growth and raises its EBIT and EBITDA margins by 2030, despite the stock currently trading at a premium P/E ratio of 135. This initiation follows recent positive momentum for Repligen, including strong Q1 2026 financial results and RBC Capital also resuming coverage with an outperform rating.
2026-06-01 21:39:42
Wolfe Research has initiated coverage on Repligen Corp. (NASDAQ:RGEN) with an outperform rating and a price target of $145.00, based on 60 times their 2027 EPS estimate. The firm believes this valuation is justified if Repligen achieves 15% annual growth and raises its EBIT and EBITDA margins by 2030, despite current InvestingPro analysis suggesting the stock is overvalued. This comes after Repligen reported strong Q1 2026 financial results, exceeding analyst expectations, and RBC Capital also resumed coverage with an outperform rating.
